The 56-day oral treatment of ApoE4-expressing AD model mice with DDL-218 that demonstrated target engagement by enhancement of SirT1 mRNA and improvement in memory was not associated with any observable adverse effects, suggesting this compound could be a promising lead candidate for AD. This evidence concerns the gene APOE and Alzheimer disease.